Home Cart Sign in  
Chemical Structure| 954126-98-8 Chemical Structure| 954126-98-8

Structure of Danirixin
CAS No.: 954126-98-8

Chemical Structure| 954126-98-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Danirixin is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible CXCR2 antagonist.

Synonyms: GSK1325756

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Danirixin

CAS No. :954126-98-8
Formula : C19H21ClFN3O4S
M.W : 441.90
SMILES Code : O=C(NC1=CC=C(Cl)C(S([C@H]2CCCNC2)(=O)=O)=C1O)NC3=C(C)C(F)=CC=C3
Synonyms :
GSK1325756
MDL No. :MFCD27987922
InChI Key :NGYNBSHYFOFVLS-LBPRGKRZSA-N
Pubchem ID :24780598

Safety of Danirixin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Danirixin

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Colorectal cancer model established with CT26 cells Oral gavage 15 mg/kg Every two days until the completion of the study In vivo treatment with danirixin (antagonists of CXCR2) promoted tumor progression in animal models established with CT26 cells. CXCR2 antagonism may function via an immune component, with CXCR2 antagonist treatment in mice resulting in reduced activated DCs and correlating with decreased Interferon gamma (IFN-g) or Granzyme B expressed CD8+ T cells. Front Immunol. 2021 May 7;12:667177

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01453478 Pulmonary Disease, Chronic Obs... More >>tructive Less << PHASE1 COMPLETED 2011-12-19 GSK Investigational Site, Nott... More >>ingham, NG11 6JS, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.31mL

2.26mL

1.13mL

22.63mL

4.53mL

2.26mL

References

 

Historical Records

Categories